KDventures AB 

0
0
+SEK0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Financials

-11,601.14%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
1.67MRevenue
-193.86MNet Income

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
BridgeBio Pharma
BBIO
Mkt Cap14.97B
BridgeBio Pharma focuses on genetic diseases and targeted therapies, similar to Karolinska Development's investment in biotech and pharmaceutical companies.
Vertex Pharmaceuticals
VRTX
Mkt Cap137.3B
Vertex Pharmaceuticals is involved in creating transformative medicines for serious diseases, paralleling Karolinska's focus on high-impact medical conditions.
Sarepta Therapeutics
SRPT
Mkt Cap2.2B
Sarepta Therapeutics specializes in precision genetic medicine, competing in the same innovative biotechnology space as Karolinska Development.
Biomarin Pharmaceutical
BMRN
Mkt Cap12.52B
BioMarin Pharmaceutical develops and commercializes innovative biopharmaceuticals, similar to Karolinska's strategy in life sciences investments.
Alnylam Pharmaceuticals
ALNY
Mkt Cap31.73B
Alnylam Pharmaceuticals works on RNAi therapeutics, a cutting-edge approach in biotech where Karolinska Development also invests.
CRISPR Therapeutics
CRSP
Mkt Cap5.58B
CRISPR Therapeutics is a leader in gene editing technology, a field relevant to Karolinska Development's interest in groundbreaking medical technologies.
Novo Nordisk
NVO
Mkt Cap201.64B
Novo Nordisk is a global healthcare company with a focus on innovative treatments for diabetes and other serious chronic conditions, aligning with Karolinska's investment focus.
Regeneron Pharmaceuticals
REGN
Mkt Cap81.77B
Regeneron Pharmaceuticals is known for its scientific capabilities in biopharmaceuticals, directly competing with Karolinska's portfolio companies.
Bio-Techne
TECH
Mkt Cap11.35B
Bio-Techne develops, manufactures, and sells biotechnology products and clinical diagnostic controls, overlapping with Karolinska's biotech interests.

About

Karolinska Development AB (publ) operates as a venture capital firm, primarily focused on providing funding to nascent companies across seed, early, and growth stages. Its investment strategy targets a wide array of life science domains, including pharmaceutical and genetic research and development, medical advancements, healthcare technology, innovative drug delivery systems, biotechnology, and specialized tools and service providers for the life science industry. The company strategically prioritizes investment opportunities within the Nordic region, specifically highlighting Sweden, Iceland, Norway, Finland, and Denmark. While the firm prefers to assume the role of a lead investor in its portfolio enterprises, it also remains open to participating in co-investment ventures. On an annual basis, it endeavors to finance a maximum of five new projects. Karolinska Development AB (publ) was established in 2003 and maintains its headquarters in Stockholm, Sweden.
Show more...
CEO
Viktor Drvota
Employees
8
Country
Sweden
ISIN
SE0002190926
WKN
000A0M84G

Listings

0 Comments

Share your thoughts

FAQ

What is KDventures AB stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on Stockholm Exchange exchange KDventures AB stocks are traded under the ticker KDV.ST.
What is KDventures AB revenue for the last year?
KDventures AB revenue for the last year amounts to 1.67M SEK.
What is KDventures AB net income for the last year?
KDV.ST net income for the last year is -193.86M SEK.
How many employees does KDventures AB have?
As of September 04, 2026, the company has 8 employees.
In which sector is KDventures AB located?
KDventures AB operates in the Health & Wellness sector.
When did KDventures AB complete a stock split?
KDventures AB has not had any recent stock splits.
Where is KDventures AB headquartered?
KDventures AB is headquartered in Solna, Sweden.